Business
miRagen Announces New Clinical Data Showing MRG-110 Positively Impacted Tissue Repair and New Blood Vessel Growth
Data included in an oral presentation at the 15th annual meeting of the Oligonucleotide Therapeutics Society Data supports advancing MRG-110 into additional
About this update from Viridian Therapeutics, Inc.
[{"type":"text","content":"Data included in an oral presentation at the 15th annual meeting of the Oligonucleotide Therapeutics Society\n Data supports advancing MRG-110 into additional clinical studies BOULDER, Colo., Oct. 16, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today new data from two Phase 1 clinical trials of MRG-110, miRagen’s microRNA-92 inhibitor, in which administration of MRG-110 was observed to increase angiogenesis, as demonstrated by increased perfusion and histological markers of neoangiogenesis, as well as reduce alpha-smooth muscle actin (α-SMA) expression, which has been show to correlate with activation of myofibroblasts. In addition, MRG-110 was safe and generally well-tolerated when given as a single intravenous dose or as three weekly intradermal doses. “We believe these Phase 1 safety, tolerability, pharmacokinetics, and biomarker data may provide mechanistic proof-of-concept for use of MRG-110 in the treatment of cardiovascular disease and certain other conditions where vascular flow is compromised,” said Paul Rubin, M.D., Executive Vice President, R&D, of miRagen Therapeutics. “When combined with the preclinical data that we have accumulated for MRG-110 in a variety of potential therapeutic settings, we believe these initial human data support advancing MRG-110 into additional clinical studies.” William S. Marshall, President and CEO of miRagen Therapeutics, added, “MRG-110 is our third product candidate to have observed proof-of-drug mechanism in humans with a good safety and tolerability profile. We believe this adds to the growing body of evidence that microRNA targeting may be a new avenue to treat complex diseases.” The two Phase 1 studies investigated MRG-110 in order to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple local administrations of MRG-110 in excisional wounds. In addition, one of the studies was a systemic dosing study assessing safety and tolerability in healthy volunteers. In small, acute wounds on normal healthy volunteers, single and multiple doses of MRG-110 appeared to: Increase angiogenesis as assessed by CD31 immunostaining, a marker of new blood vessel growth;Increase peri-wound perfusion, as assesse...